Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hugo Nodarse-Cuni"'
Autor:
Andréa Marques Vieira da Silva, Lucia Elena Alvarado-Arnez, Tamiris Azamor, Leonardo Ribeiro Batista-Silva, Thyago Leal-Calvo, Ohanna Cavalcanti de Lima Bezerra, Marcelo Ribeiro-Alves, Fernanda de Souza Gomes Kehdy, Patrícia Cristina da Costa Neves, Camilla Bayma, Jane da Silva, Alessandro Fonseca de Souza, Marcelo Muller, Elisabete Ferreira de Andrade, Ana Carolina Magalhães Andrade, Eliane Matos dos Santos, Janaína Reis Xavier, Maria De Lourdes De Sousa Maia, Rolando Páez Meireles, Hugo Nodarse Cuni, Guilherme Becker Sander, Paulo Dornelles Picon, Denise C S Matos, Milton Ozório Moraes
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
Sustained virologic response (SVR) in chronic hepatitis C (CHC) treatment denotes that the host genetics controls the immune response and unequivocally contribute to viral clearance or disease severity. In this context, single nucleotide polymorphism
Externí odkaz:
https://doaj.org/article/7f83e57550ec48399e31a3e594db5543
Autor:
Hugo Nodarse-Cuni, Francisco Hernández-Bernal, Idelsis Esquivel-Moynelo, Bello-Rivero Iraldo, Claudia Martínez Suarez, Gerardo Guillén-Nieto, Yaquelin Duncan-Roberts, Verena Muzio-Gonzalez, Ivan Campa-Legrá
Background: As the outbreak of COVID-19 has accelerated, an urgent need for finding strategies to combat the virus is growing. Results from in vitro studies suggest that a combination of IFN type I and Type II may be effective against SARS-CoV. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c80ecb1ed9b42f1428ed7dc7d387b23f
https://doi.org/10.21203/rs.3.rs-28958/v2
https://doi.org/10.21203/rs.3.rs-28958/v2
Publikováno v:
Revista Cubana de Medicina, Vol 57, Iss 4 (2018)
RESUMEN Escasas áreas geográficas escapan a la pandemia que representa la infección viral por virus C. Los porcentajes de evolución a la cronicidad son altos: entre 20-30 % desarrollan cirrosis hepática y sus complicaciones dentro de 30 años. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::3b2efeff11403f3270eb4f601b01c7d3
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232018000400005&tlng=es
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232018000400005&tlng=es
Autor:
Yanet Cordero-Vasallo, Anselmo Abdo-Cuza, Odalys González-Dias, Julio Valdivia-Arencibia, Alicia Rodríguez-Sotolongo, Sandra Arencibia-Larin, Ernesto Delgado-Almora, Jorge L. Leiva-Torres, Niurka Verdecia-Gorrita, Yusmel Rivero-Yi, Hugo Nodarse-Cuni, Miguel A. Blanco-González, Julio C. Hernández-Perera, Carlos Gutiérrez-Gutiérrez, Tania González-Fernández, Lisy Vento-Buigues, Thalía Gómez-Pariente, Janete Treto-Ramirez, Roberto Castellanos-Gutiérrez, Daymiris Mendez-Felipe, Rafael Machado-Martinez, Katia Arocha-Stalella, Juliette Suárez-López, Nilda Bejerano-Gil
Publikováno v:
Journal of Renal Endocrinology. 7:e05-e05
Introduction: Patients diagnosed with end-stage chronic kidney disease on a hemodialysis program (HDP) represent a risk group for COVID-19. Scientific societies have developed guidelines for the prevention of contagion, but there is no prophylactic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9b2831270a604248b24804cae492f98
https://doi.org/10.34172/jre.2021.05
https://doi.org/10.34172/jre.2021.05
Autor:
Hugo Nodarse-Cuní, Pedro A López-Saura
Publikováno v:
Biotecnología Aplicada, Vol 34, Iss 1, Pp 1211-1217 (2017)
Externí odkaz:
https://doaj.org/article/30abe79e9ff84927ae99c4e549af8ad1
Autor:
Hugo Nodarse-Cuní, Enrique Arús-Soler, Luis L Rivera-Reimón, Marlén Pérez-Lorenzo, Marcia Samada-Suárez, Waldo O García-Ferrera, Yoan A Sánchez-Rodríguez, Daymela Pupo-Oliveros, Angel Obregón-Moreno, Ivis Umpierre-García, Orelvis Martínez-Martínez, Antonio Moret-Pérez, Yaimé González-González, Yuliet Bermúdez-Hernández, Elizeth García-Iglesias, Odalys C Lazo-Diago, Pedro López-Saura
Publikováno v:
Biotecnología Aplicada, Vol 29, Iss 3, Pp 184-188
The treatment of chronic hepatitis C with interferon alpha (IFN-a) is widely used. However, the relapse rate is high, and sustained response is only in 10-20%. A combined treatment based on the synergic antiviral effects described for IFN-a and ribav
Externí odkaz:
https://doaj.org/article/f3c2c2e4ff484170b52c4545adaabdd3
Autor:
Marlen I Castellanos-Fernández, Ariadna González-García, Hugo Nodarse-Cuní, Luis Calzadilla-Bertot, Yadina Martínez-Pérez, Yoan A Sánchez Rodríguez, Zaily Dorta-Guridi, Ana L Torres González, Enrique R Arús Soler, Yaritza López Díaz
Publikováno v:
Biotecnología Aplicada, Vol 32, Iss 4, Pp 4201-4207
Externí odkaz:
https://doaj.org/article/56b8e40b598d42fcb8c97f1776ff1272
Autor:
Marisa Boff Costa, Paulo Dornelles Picon, Guilherme Becker Sander, Hugo Nodarse Cuni, Carmen Valenzuela Silva, Rolando Páez Meireles, Ana Carolina Magalhães Andrade Góes, Nadia Maria Batoreu, Maria de Lourdes de Sousa Maia, Elizabeth Maciel Albuquerque, Denise Cristina de Souza Matos, Pedro Lopez Saura
Publikováno v:
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-8 (2018)
Abstract Background Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was deve
Externí odkaz:
https://doaj.org/article/ada7798ae8e14c05b74b5ec1fb74647d